Opendata, web and dolomites

DECODE SIGNED

reDucing the health and Economic COst of Diagnostic uncErtainty: launch and randomized control trial of the first validated bacterial versus viral test

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 DECODE project word cloud

Explore the words cloud of the DECODE project. It provides you a very rough idea of what is the project "DECODE" about.

elevated    body    validated    cleared    regulatory    trial    suitable    500    inappropriate    amr    resistance    antimicrobial    burden    clinicians    tool    dach    trade    leads    applicability    reduces    superiority    capillary    demonstrated    acute    outcomes    gaps    clinically    serum    15    indistinguishable    expand    platform    workflow    routinely    confidence    blood    suspected    children    utility    commercially    patients    viral    avoidable    initiate    gap    infections    healthcare    misuse    double    runs    health    rct    reducing    settings    market    distinguishing    samples    release    decodes    bacterial    actionable    diagnostics    constraints    memed    compatible    validation    world    data    blind    externally    global    minutes    threats    solution    instances    conduct    diagnostic    primary    patient    problem    care    complete    decode    enrolling    biomarkers    hospitalization    efforts    clinician    randomized    bv    immune    pioneering    economic    broad    infection    clinical    gather    poc    concurrently    inferior    key    share    risk    thousands    multicentre    routine    decide    fight   

Project "DECODE" data sheet

The following table provides information about the project.

Coordinator
MEMED DIAGNOSTICS LTD 

Organization address
address: NAHUM HETH STREET 5
city: TIRAT CARMEL
postcode: 39120
website: www.me-med.com

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Israel [IL]
 Total cost 3˙571˙427 €
 EC max contribution 2˙499˙999 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-2
 Funding Scheme SME-2
 Starting year 2020
 Duration (year-month-day) from 2020-01-01   to  2021-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    MEMED DIAGNOSTICS LTD IL (TIRAT CARMEL) coordinator 2˙499˙999.00

Map

 Project objective

Problem: Clinicians routinely face diagnostic uncertainty because acute infections are often clinically indistinguishable and today’s diagnostics have constraints. This uncertainty leads to inappropriate patient management, including antimicrobial misuse and avoidable hospitalization. The associated health economic burden are inferior patient outcomes, elevated costs, and antimicrobial resistance (AMR), one of the top 10 threats to global health. Potential solution: In many instances, the clinician only needs to know with confidence if the infection is bacterial or viral to decide how to manage a patient suspected to have an acute infection. We have developed and validated MeMed BV™ - a pioneering test for distinguishing between bacterial and viral infections that decodes the body’s immune response to infection. BV™ has been both double-blind and externally validated in clinical studies enrolling thousands of patients and demonstrated superiority to biomarkers in routine use. Concurrently, we have developed Key™, an easy-to-use POC platform that runs BV™ in 15 minutes. Gap: Broad impact of BV™ and market share require high-risk efforts to address the following major gaps: 1. Real world evidence of usage and impact on workflow. 2. Validation of clinical utility in a randomized control trial (RCT). 3. Expand applicability to primary care settings. Proposed objectives: 1. To initiate market release in DACH and gather real world data. 2. To conduct a multicentre RCT enrolling 500 children. 3. Complete development of BV™ compatible with capillary blood. Impact: DECODE will take BV™ on Key™ from a test regulatory cleared for use to one that is available commercially and adopted in routine care, has validated clinical utility and is suitable for both serum and capillary blood samples. By providing an actionable tool that reduces diagnostic uncertainty, this project will improve patient outcomes while reducing healthcare costs and help fight AMR.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "DECODE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "DECODE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

TAPPXSSAI (2019)

Development of a system for automatic ad insertion into on-demand streaming video to provide new monetization mechanisms to the media industry

Read More  

PRIVATETRACK (2019)

PRIVATETRACK: Privacy-friendly, low-power intelligent room occupancy detection and people counting.

Read More  

COUNTMITMENT (2019)

NATURAL CAPITAL ACCOUNTANCY TO IMPROVE REPORTING AND ENVIRONMENTAL PERFORMANCE

Read More